- Home
- DXLG vs NTRB Comparison
DXLG vs NTRB Comparison
Compare DXLG & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | NTRB |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 36.0M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DXLG | NTRB |
|---|---|---|
| Price | $0.64 | $4.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 25.7K | 6.4K |
| Earning Date | 05-28-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $435,017,000.00 | $2,036,651.00 |
| Revenue This Year | $3.85 | $30.17 |
| Revenue Next Year | $4.09 | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $2.80 |
| 52 Week High | $1.58 | $8.63 |
Technical Indicators
Market Signals| Indicator | DXLG | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 83.44 |
| Support Level | $0.62 | $4.37 |
| Resistance Level | $0.74 | $4.50 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 58.65 | 96.36 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.